JP7249279B2 - がんの相乗的治療方法 - Google Patents

がんの相乗的治療方法 Download PDF

Info

Publication number
JP7249279B2
JP7249279B2 JP2019531255A JP2019531255A JP7249279B2 JP 7249279 B2 JP7249279 B2 JP 7249279B2 JP 2019531255 A JP2019531255 A JP 2019531255A JP 2019531255 A JP2019531255 A JP 2019531255A JP 7249279 B2 JP7249279 B2 JP 7249279B2
Authority
JP
Japan
Prior art keywords
dose
chemotherapeutic agent
salmonella typhimurium
agent
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531255A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500922A5 (https=
JP2020500922A (ja
Inventor
エー．ソルツマン ダニエル
Original Assignee
サルスペラ，リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サルスペラ，リミティド ライアビリティ カンパニー filed Critical サルスペラ，リミティド ライアビリティ カンパニー
Publication of JP2020500922A publication Critical patent/JP2020500922A/ja
Publication of JP2020500922A5 publication Critical patent/JP2020500922A5/ja
Priority to JP2022143644A priority Critical patent/JP2022171776A/ja
Application granted granted Critical
Publication of JP7249279B2 publication Critical patent/JP7249279B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019531255A 2016-12-07 2017-12-06 がんの相乗的治療方法 Active JP7249279B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022143644A JP2022171776A (ja) 2016-12-07 2022-09-09 がんの相乗的治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662430962P 2016-12-07 2016-12-07
US62/430,962 2016-12-07
PCT/US2017/064813 WO2018106754A1 (en) 2016-12-07 2017-12-06 Methods of synergistic treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022143644A Division JP2022171776A (ja) 2016-12-07 2022-09-09 がんの相乗的治療方法

Publications (3)

Publication Number Publication Date
JP2020500922A JP2020500922A (ja) 2020-01-16
JP2020500922A5 JP2020500922A5 (https=) 2021-01-28
JP7249279B2 true JP7249279B2 (ja) 2023-03-30

Family

ID=62492129

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531255A Active JP7249279B2 (ja) 2016-12-07 2017-12-06 がんの相乗的治療方法
JP2022143644A Pending JP2022171776A (ja) 2016-12-07 2022-09-09 がんの相乗的治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022143644A Pending JP2022171776A (ja) 2016-12-07 2022-09-09 がんの相乗的治療方法

Country Status (4)

Country Link
US (3) US11576936B2 (https=)
EP (1) EP3550976A4 (https=)
JP (2) JP7249279B2 (https=)
WO (1) WO2018106754A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022171776A (ja) * 2016-12-07 2022-11-11 サルスペラ，リミティド ライアビリティ カンパニー がんの相乗的治療方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3652318A1 (en) 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2020014543A2 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CA3162344A1 (en) * 2019-12-26 2021-07-01 Aydin S. MORADIAN Methods and agents for treating solid tumor cancers
EP3922255A1 (en) * 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
AU2022404718A1 (en) 2021-12-09 2024-05-30 Prokarium Limited Combination cancer therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100098665A1 (en) 2004-04-29 2010-04-22 Botanic Oil Innovations, Inc. Method of cancer treatment
WO2016145974A1 (zh) 2015-03-17 2016-09-22 南京华贞生物医药科技有限公司 基因工程菌vnp20009-m在制备预防和治疗癌症转移的药物上的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6531164B1 (en) 1998-12-03 2003-03-11 The Crede Family Trust Enteral pharmaceutical preparation
AU7856100A (en) 1999-10-04 2001-05-10 Vion Pharmaceuticals, Inc. Methods for treating solid tumors with irradiation and bacteria
WO2002026819A2 (en) 2000-09-26 2002-04-04 Roger Williams Hospital Recombinant bcg vaccines for the prevention and treatment of cancer
US20080107758A1 (en) 2001-06-15 2008-05-08 Cuticeuticals, Inc. Topical steroid spray with botanic seed oils
WO2003063593A1 (en) 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
DE10208653A1 (de) 2002-02-28 2003-09-18 Medinnova Ges Med Innovationen Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren
EP1644492B1 (en) 2003-06-18 2009-01-07 Genelux Corporation Modified recombinant vaccinia viruses, uses thereof
US7897194B2 (en) 2006-04-18 2011-03-01 Botanic Oil Innovations, Inc. Synergistic super potent antioxidant cold pressed botanic oil blends
US20050244375A1 (en) 2004-04-29 2005-11-03 Leonard Arnold S Composition and method of cancer treatment
US20070128301A1 (en) 2005-09-07 2007-06-07 Saltzman Daniel A Immune enhancement by seed oil and/or seed flour
EP1934349A4 (en) 2005-08-30 2009-05-27 Commw Scient Ind Res Org BACTERIAL INTRODUCTION OF BIOLOGICALLY ACTIVE POLYPEPTIDES
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
US9127284B2 (en) 2012-05-04 2015-09-08 The University Of Hong Kong Modified bacteria and their uses thereof for the treatment of cancer or tumor
JP7249279B2 (ja) * 2016-12-07 2023-03-30 サルスペラ，リミティド ライアビリティ カンパニー がんの相乗的治療方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100098665A1 (en) 2004-04-29 2010-04-22 Botanic Oil Innovations, Inc. Method of cancer treatment
WO2016145974A1 (zh) 2015-03-17 2016-09-22 南京华贞生物医药科技有限公司 基因工程菌vnp20009-m在制备预防和治疗癌症转移的药物上的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Oncotarget, Feb 2016, Vol. 7, No. 11, pp. 12783-12790
Veterinary Medicine and Science, Jun 2016, Vol. 2, pp. 179-190

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022171776A (ja) * 2016-12-07 2022-11-11 サルスペラ，リミティド ライアビリティ カンパニー がんの相乗的治療方法
US12090179B2 (en) 2016-12-07 2024-09-17 Salspera, Llc Methods of synergistic treatment of cancer

Also Published As

Publication number Publication date
EP3550976A4 (en) 2020-06-10
US20240091275A1 (en) 2024-03-21
JP2022171776A (ja) 2022-11-11
WO2018106754A1 (en) 2018-06-14
US20240415898A1 (en) 2024-12-19
JP2020500922A (ja) 2020-01-16
US11576936B2 (en) 2023-02-14
EP3550976A1 (en) 2019-10-16
US12090179B2 (en) 2024-09-17
US20200085883A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
JP7249279B2 (ja) がんの相乗的治療方法
JP6616319B2 (ja) 腫瘍崩壊ワクシニアウィルス
Saltzman et al. Low dose chemotherapy combined with attenuated Salmonella decreases tumor burden and is less toxic than high dose chemotherapy in an autochthonous murine model of breast cancer
JP3013896B2 (ja) ヒトマンガンスーパーオキシドジスムターゼを含む薬剤組成物
CN116948931A (zh) 靶向肿瘤和治疗癌症的细菌
JP2777074B2 (ja) ポリペプチドおよびその製造方法
KR20250124795A (ko) 인터루킨-12의 분비를 위한 재조합 발현 벡터 및 이로 형질전환된 약독화 살모넬라 균주
CN113499450B (zh) 用于治疗疼痛的组合物
KR20220121245A (ko) 고형 종양 암의 치료 방법 및 제제
JP7412576B2 (ja) 腎がんの相乗的治療におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の適用
EP3535401B1 (en) Microorganism for delivering drug for treatment of gastrointestinal disease, which expresses and secretes cystatin, and pharmaceutical composition for preventing or treating gastrointestinal disease, which includes the same
HK40073241A (en) Methods and agents for treating solid tumor cancers
KR20240015029A (ko) 카탈레이스 분비를 위한 재조합 발현 벡터 및 이로형질전환된 대장균 균주
ES2847214T3 (es) 8-oxo-dGTP para la prevención y tratamiento de tumores y aplicaciones del mismo
CN114272248B (zh) 一种化疗免疫凝胶及其制备方法与应用
WO2026030756A2 (en) Liver disease treatments using attenuated strains of salmonella typhimurium
JP2024533400A (ja) 腫瘍の非毒性コロニー形成のために操作されたサルモネラ菌
KR101285470B1 (ko) ＴＮＦ－α를 발현하는 살모넬라를 포함하는 항암치료 보조제
WO2025256277A1 (zh) 黑素细胞刺激素α-MSH在治疗肝癌中的应用
Granci et al. O004 INCREASED ANTITUMOUR EFFECT OF 5-FLUOROURACIL BY N-3 POLYUNSATURATED FATTY ACIDS IN NUDE MICE XENOGRAFTED WITH HUMAN COLORECTAL TUMOURS
CN105709217A (zh) Psat1及其产物在制备调节胰岛素敏感性的药物中的用途
Shapiro et al. O005 FISH OIL FEEDING IMPROVES LONG-TERM SURVIVAL AFTER SURGICAL RESECTION OF A TUMOR: PROBABLE ROLE OF PERI-OPERATIVE IMMUNITY AGAINST MICRO-METASTASES

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201207

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220909

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220909

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220927

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221028

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230317

R150 Certificate of patent or registration of utility model

Ref document number: 7249279

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250